show episodes
 
R
RAVE: Rheumatoid Arthritis Vital Education
 
Dr. Clifton Bingham from the Johns Hopkins Arthritis Center begins with a review of current best practices, including the issues related to diagnosis. Dr. George Lawry will follow with an overview of the risks and benefits of biologic therapy for patients with RA before Dr. Bingham presents on emerging DMARDs.The second half of the nearly 2 hour presentation covers the subject of comorbidities, presented by Dr. Lawry, on how to recognize comorbidities and how to best manage them. Dr. Bingham ...
 
Loading …
show series
 
Professor Jonathan Kay (Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester, Massachusetts, USA) tells Editor-in-Chief of RMD Open Bernard Combe why he supports the switch from branded drugs to their cheaper biosimilar.They spoke at the EULAR conference 2017, ...…
 
Tópicos em Dermatologia – Maio de 2017. Os episódios do Dermacast “Tópicos em Dermatologia” tem por objetivo trazer resenhas dos artigos mais relevantes e atuais publicados nas revistas científicas de dermatologia do Brasil e do mundo, para promover o estímulo a procura direta por conhecimento em dermatologia nessas fontes primárias de conhecim ...…
 
Main Topic Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013. Tocilizumab (Actemra) vs adalimumab (Humira) with background methotrexate Biological drug ...…
 
This week we discuss a head to head trial of Abatacept (Orencia) vs. adalimumab (Humira) as monotherapy in rheumatoid arthritis. Discuss the suicide of Aaron Swartz in the context of academic publishing, share a few apps we use to calculate DAS scores, and unanimously recommend Dropbox to everyone. Abatacept (Orencia) vs. adalimumab (Humira) We ...…
 
After a break for Christmas, we're back with a three part episode. First, we discuss tofacitinib (Xeljanz), the new DMARD for rheumatoid arthritis. We primarily discuss the phase three trials but get into some of the side effects noticed in the phase 2 trials as well. Michael then does a bit of a monologue on using text-macro programs to improv ...…
 
A
Annals of Internal Medicine Podcast
 
Summary of the December 18, 2012 issue, including articles on reducing hospital length of stay, adalimumab therapy for hidradenitis suppurativa, risk classification of advanced colorectal neoplasia, epidural injections for sciatica, Clostridium difficile-associated diarrhea, and pay-for-performance, as well as the USPSTF recommendation statemen ...…
 
A
Annals of Internal Medicine Podcast
 
Summary of the December 18, 2012 issue, including articles on reducing hospital length of stay, adalimumab therapy for hidradenitis suppurativa, risk classification of advanced colorectal neoplasia, epidural injections for sciatica, Clostridium difficile-associated diarrhea, and pay-for-performance, as well as the USPSTF recommendation statemen ...…
 
J
JointHealth™ podcast - Evidenced Based Information on Arthritis
 
Topics discussed with Dr. Shojania include: The challenge of getting diagnosed; The impact of the diagnosis; Accepting one's diagnosis; Learning about one's treatment options; The basics about non-steroidal anti-inflammatory medications (NSAIDs) - when do they get used and why, what do they not do; The basics about disease modifying anti-rheuma ...…
 
Speed
Series preference
1x
1x
Volume
100%
/

Google login Twitter login Classic login